arrow
E

Elias Jabbour

the university of texas-md anderson cancer center
H指数:115
被引数:5.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

An all-oral triplet regimen (decitabine/cedazuridine, venetoclax, and gilteritinib) for newly diagnosed and relapsed/refractory FLT3-mutated AML and high-risk MDS

口服三联方案(地西他滨/西达苯胺、维奈克拉和吉列替尼)用于新诊断和复发/难治性FLT3突变急性髓系白血病及高风险骨髓增生异常综合征

2026-10-130
OAAI
Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia

新诊断急性髓系白血病中NPM1突变相关的临床结局

Cancer
IF5.1
2026-08-130
OAAI
Comparison of obecabtagene autoleucel versus an external control arm in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia

比较obeccabtagene autoleucel与外部对照臂在复发/难治性B细胞急性淋巴细胞白血病患者中的疗效

Leukemia
IF13.4
2026-07-170
OAAI
Predictors of survival in adults with B-cell acute lymphoblastic leukemia treated with blinatumomab and/or inotuzumab ozogamicin in first salvage

成人B细胞急性淋巴细胞白血病患者在首次挽救治疗中使用blinatumomab和/或inotuzumab ozogamicin的生存预测因子

Leukemia
IF13.4
2026-07-160
OAAI
Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia

奥佐米星依诺他单抗疗法治疗成人急性淋巴细胞白血病的可测量残留病灶

2026-06-270
OAAI
Inotuzumab ozogamicin in individuals with Down syndrome and acute lymphoblastic leukemia

奥佐米星在唐氏综合征和急性淋巴细胞白血病患者中的应用

Leukemia
IF13.4
2026-06-030
PRE
Predictors of Relapse and Post-Relapse Outcomes After Frontline Blinatumomab in Philadelphia Chromosome-Negative B-ALL

Ph1阴性B-ALL一线治疗使用blinatumomab后复发的预测因素及复发后结局

2026-05-170
OAAI
Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy

低强度治疗下急性髓系白血病中ASXL1突变的预后影响

Cancer
IF5.1
2026-05-060
OA
Outcome of second-line therapy in adult B-cell acute lymphoblastic leukemia

成人B细胞急性淋巴细胞白血病的二线治疗结局

Cancer
IF5.1
2026-04-090
PRE
Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes

异基因造血干细胞移植对高风险骨髓增生异常综合征患者的影响

2026-03-270
OAAI
Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia

更正:维奈克拉联合FLAG-IDA诱导和巩固治疗新诊断及复发或难治性急性髓系白血病的长期结果

Leukemia
IF13.4
2025-12-100
OAAI
A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemias

DS-1594 menin抑制剂的1/2期研究:在复发/难治性急性白血病中的应用

2025-11-270
OAAI
A tour of leukemia progress in 2025, viewed through the MD Anderson leukemia research lens

2025年白血病研究进展回顾:通过MD Anderson白血病研究视角进行审视

Cancer
IF5.1
2025-10-230
OAAI